The U.S. gave crypto one of its biggest regulatory jolts in years.  With the signing of the Guiding and Establishing National Innovation for U.S. Stablecoins (“GENIUS”) Act stablecoins now have a legal framework. The GENIUS Act is part of a broader push to accelerate the development of emerging technologies in the U.S., from artificial intelligence to quantum computing. That same push is showing up in the patent world, where the U.S. Patent and Trademark Office (“USPTO”) and Patent Trial and Appeal Board (“PTAB”) are beginning to clarify how blockchain-related inventions can clear long-standing Section 101 hurdles.

Just as the GENIUS Act provides clarity for stablecoins, a recent PTAB decision is beginning to provide clarity for blockchain patents. In Ex Parte David L. Newman, the PTAB reversed the Examiner’s rejection of the claims under 35 U.S.C. § 101 and provided some useful discussion of how the USPTO (and patent applicants) should approach blockchain-related patents. The claims at issue relate to “securely storing data across a network in a multi-dimensional distributed database” in order to “process[] license contracts, including computing proportional payments related thereto, using blockchains comprising supplemental fork blocks that comprise custodian addresses.”

The Examiner had rejected the claims as directed to the abstract idea of “payment, distribution, and pricing for two users bound by a contractual relationship,” concluding that the additional elements in the claims do not integrate the abstract idea into a practical application. In the Examiner’s view, the invention simply used “a computer as a tool to perform an abstract idea.” The PTAB agreed in part – acknowledging that the claims involved an abstract idea because “[i]t is well settled that commercial interactions involving payment transactions or contractual agreements, are the type of judicially excepted abstract ideas categorized as methods of organizing human activity.”

However, the Board drew the line at step 2 of the Alice analysis. Unlike the Examiner, the Board determined that the claims integrate the abstract idea into a practical application “by improving the technical functioning of the recited blockchain by transforming it into a multi-dimensional database slidechain that allows for the execution and simultaneous processing of supplemental fork blocks along the slidechain.” In other words, the invention did more than implement a business method on a generic computer—it changed how the blockchain itself operates.  As the Board explained, the claims “recite[] steps that transform the blockchain itself so as to allow for improved processing, i.e., simultaneous processing of supplemental fork blocks along the slidechain… [and] uses the recited abstract idea in a meaningful way beyond generally linking its use to a particular technological environment.”

Section 101 of the Patent Act has historically been a major hurdle for patent applicants attempting to claim improvements in blockchain technology.  But as we discussed in relation to a recent PTAB decision related to quantum computing, patent applicants in blockchain-related industries can now find guidance in decisions like Ex Parte David L. Newman to overcome rejections based on 35 U.S.C. § 101. Specifically, applicants should use their specification to clearly articulate how their invention improves “the performance of a computer” and/or “the functionality of the blockchain and the processing thereof.”

The Proskauer Intellectual Property Team is continuing to monitor the evolving guidance on patent eligibility of emerging technologies. With Congress providing a regulatory framework for stablecoins and the PTAB recognizing technical improvements in blockchain, these parallel developments signal a more supportive environment for innovators. We welcome questions about how these shifts may affect your patent strategy in the crypto and broader emerging technology space.

Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of Baldassare Vinti Baldassare Vinti

Baldassare (“Baldo”) Vinti is the head of Proskauer’s Intellectual Property Litigation Group.

Baldo is a first-chair trial lawyer known for navigating complex, bet-the-company intellectual property disputes across industry verticals and next-generation technologies. With over 25 years of experience, Baldo represents leading global companies…

Baldassare (“Baldo”) Vinti is the head of Proskauer’s Intellectual Property Litigation Group.

Baldo is a first-chair trial lawyer known for navigating complex, bet-the-company intellectual property disputes across industry verticals and next-generation technologies. With over 25 years of experience, Baldo represents leading global companies and universities in patent, trade secret, false advertising, consumer class actions and technology-related breach of contract litigation in federal and state courts as well as before the International Trade Commission.

Baldo is particularly sought after for his courtroom skill and strategic depth, having led trials, arbitrations and appeals in high-stakes disputes involving technologies ranging from pharmaceuticals and medical devices to encryption, digital media, diagnostics, mobile platforms and software. Baldo has represented global corporations, including Arkema S.A., British Telecommunications PLC, Church & Dwight Co., Inc., Henry Schein, Inc., Maidenform Brands Inc., Mitsubishi Electric Corp., Ossur North America Inc., Panasonic Corp., Sony Corp., Welch Foods, Inc. and Zenith Electronics LLC.

With a background in pharmacy, Baldo brings deep domain expertise to pharmaceutical litigation. He has a proven record of driving successful outcomes in complex pharmaceutical milestone payment, royalty and licensing disputes—often stemming from collaboration agreements, co-development deals, and M&A transactions—where the financial and strategic stakes run high.

In addition to representing corporate clients, Baldo works closely with university innovation and technology transfer offices to maximize the financial return of research investments. He develops tailored IP asset optimization strategies and aggressively enforces intellectual property rights to protect and monetize core innovations—whether through high-value licensing agreements, shaping and advancing spin-out company development, or successful litigation.

Baldo also provides strategic counsel on IP due diligence, complex licensing, IP structuring, patentability and freedom-to-operate analyses, and infringement and validity opinions. He advises boards and executive teams on aligning IP strategy with business objectives, mitigating risk and maximizing the value of innovation assets.

A frequent author and commentator on intellectual property topics, Baldo has been quoted in the National Law Journal, Bloomberg BNA, Law360, Westlaw Journal and Inside Counsel magazine. He is also a regular contributor to articles published in Medical Product Outsourcing magazine that deal with the medical device industry.

Baldo served as a judicial intern for Hon. John E. Sprizzo of the United States District Court for the Southern District of New York and for Hon. Charles A. LaTorella of the New York Supreme Court.

Photo of Alan S. Teran, Ph.D. Alan S. Teran, Ph.D.

Alan S. Teran, Ph.D., is an associate in the Litigation Department and Intellectual Property Group.

His practice focuses on a variety of intellectual property issues, including worldwide patent portfolio development and litigation. Alan also has experience with in-house legal and compliance matters, including…

Alan S. Teran, Ph.D., is an associate in the Litigation Department and Intellectual Property Group.

His practice focuses on a variety of intellectual property issues, including worldwide patent portfolio development and litigation. Alan also has experience with in-house legal and compliance matters, including product counseling, commercial contracts, and privacy.

Alan has expertise in semiconductor devices and fabrication as well as experience with a wide range of technologies, including augmented/virtual reality-based software solutions; material processing operations; control systems; integrated circuits; machine learning-based financial services software; media and mobile technology; medical devices; and secondary batteries.

Alan is a registered patent attorney before the U.S. Patent & Trademark Office; and a Certified Information Privacy Professional in the United States (CIPP/US) with the International Association of Privacy Professionals (IAPP).

Alan received his Ph.D. in Electrical Engineering at the University of Michigan, where his research focused on energy harvesting technologies and semiconductor physics for Internet-of-Things and medical applications.